Fukui Yasuhiro, Kashiwagi Shinichiro, Takada Koji, Goto Wataru, Asano Yuka, Morisaki Tamami, Noda Satoru, Takashima Tsutomu, Onoda Naoyoshi, Hirakawa Kosei, Ohira Masaichi
Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
Gan To Kagaku Ryoho. 2017 Nov;44(12):1092-1094.
We investigated into association of quality of life(QOL)and prognosis of breast cancer patients who underwent neoadjuvant chemotherapy(NAC). We retrospectively studied 228 patients with breast cancer who were performed NAC during a period between 2007 and 2015. TheQ OL score was measured with"The QOL Questionnaire for Cancer Patients Treated with Anticancer Drugs(QOL-ACD)". We evaluate association between QOL score with antitumor effect and prognosis. Changes in the QOL score between before and after NAC were compared as well. We divided 2 groups by QOL-ACD scoreinto high and low groups. Therapeautic effect of NAC on 75 patients were pathological complete response(pCR). QOL-ACD score was not significantly associated with pCR rate in both high and low groups(p=0.199). High group was significantly associated with higher survival rate in both of disease free survival(p=0.009, logrank)and overall survival(p=0.040, logrank). QOLACD score decreased after NAC in both of pCR and non-pCR patients. In conclusion, QOL evaluation using QOL-ACD could be an indicator of breast cancer patients' prognosis who underwent NAC.
我们调查了接受新辅助化疗（NAC）的乳腺癌患者的生活质量（QOL）与预后之间的关联。我们回顾性研究了2007年至2015年期间接受NAC治疗的228例乳腺癌患者。使用“抗癌药物治疗癌症患者生活质量问卷（QOL-ACD）”测量QOL得分。我们评估了QOL得分与抗肿瘤效果及预后之间的关联。同时比较了NAC前后QOL得分的变化。我们根据QOL-ACD得分将患者分为两组，即高分组和低分组。NAC对75例患者的治疗效果为病理完全缓解（pCR）。高分组和低分组的QOL-ACD得分与pCR率均无显著关联（p = ０.199）。高分组在无病生存期（p = ０.009，对数秩检验）和总生存期（p = ０.040，对数秩检验）方面均与较高的生存率显著相关。pCR和非pCR患者在NAC后QOL-ACD得分均下降。总之，使用QOL-ACD进行QOL评估可能是接受NAC治疗的乳腺癌患者预后的一个指标。
